By targeting the active sites of HSP90, inhibitors of HSP90 inhibit its chaperone activity, interrupt multiple signaling pathways involved in tumor progression, cut off the tumor cell nutrition supply, block collateral circulation, and reduce tumor resistance caused by targeting a single factor. This evidence concerns the gene HSP90AB1 and neoplasm.